Amylyx Pharmaceuticals (AMLX) Earnings Analysis

Amylyx Pharmaceuticals (AMLX) next reports earnings on 2026-08-06, consensus EPS -0.36 USD. Last quarter (2026-05-07) it missed with EPS -0.37 USD vs -0.34 USD est (-8.8%). It has beaten estimates in 3/5 recent quarters (60%). Trailing P/E -11.96.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does AMLX next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-0.36 USD
Revenue estimaten/a

AMLX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-0.37 USD-0.34 USD-8.8%Miss
2026-03-03-0.3 USD-0.31 USD+3.2%Beat
2025-11-06-0.37 USD-0.43 USD+14%Beat
2025-05-08-0.42 USD-0.45 USD+6.7%Beat
2025-03-04-0.55 USD-0.49 USD-12.2%Miss

Beat rate: 3/5 (60%) over reported quarters with consensus data.

AMLX valuation and analyst view

Trailing P/E-11.96
Trailing EPS-1.3577 USD
Price / book7.16
Dividend yield0.00%
Market cap1.48B
Analyst consensusBuy (10 buy / 1 hold / 0 sell)
Avg price target29.75 USD

Related research pages

Frequently asked questions

When is Amylyx Pharmaceuticals (AMLX)'s next earnings date?

Amylyx Pharmaceuticals is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.36 USD.

Did AMLX beat earnings last quarter?

In its 2026-05-07 report, AMLX posted EPS of -0.37 USD versus a -0.34 USD estimate — a miss of 8.8%.

What is AMLX's earnings track record?

Over the last 5 reported quarters with consensus data, AMLX beat estimates 3 times (60%).

What is AMLX's current P/E ratio and EPS?

AMLX trades at a trailing P/E of -11.96 on trailing EPS of -1.3577011407757507 USD.

What do analysts rate AMLX?

Analyst consensus is "Buy" across 11 ratings (0 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 29.75 USD.